• 1
    Mackillop WJ, Fu H, Quirt CF, et al. Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys. 1994; 30: 221228.
  • 2
    Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003; 21: 555563.
  • 3
    O'Sullivan B, Mackillop W, Grice B, et al. The influence of delay in the initiation of definitive radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys. 1998; 42: S97.
  • 4
    Fortin A, Bairati I, Albert M, Moore L, Allard J, Couture C. Effect of treatment delay on outcome of patients with early-stage head and neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 52: 929936.
  • 5
    Brouha XD, Op De Coul B, Terhaard CH, Hordijk GJ. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol. 2000; 25: 215218.
  • 6
    Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol. 1997; 44: 137141.
  • 7
    Nam RK, Jewett MA, Krahn MD, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol. 2003; 10: 18911898.
  • 8
    Moul JW, Sun L, Amling CL, et al. How long can radical prostatectomy (RP) safely be delayed? CPDR's experiences from 3324 cases. J Urol. 171(Suppl 4): 312.
  • 9
    American Joint Committee on Cancer. AJCC Cancer Staging Manual. 4th ed. Philadelphia: Lippincott–Raven, 1992.
  • 10
    D'Amico AV, Cote K, Loffredo M, Renshaw AA, Shultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002; 20: 45674573.
  • 11
    Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986; 5: 255260.
  • 12
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Rad Onc Biol Phys. 1997; 37: 10351041.
  • 13
    D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntingt). 2001; 15: 10491059.
  • 14
    Pollack A, Zagars GK, Starkschall G. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Rad Onc Biol Phys. 2002; 53: 10971105.
  • 15
    Cheung R, Tucker SL, Dong L, Kuban D. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Rad Onc Biol Phys. 2003; 56: 12341240.
  • 16
    Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Rad Onc Biol Phys. 2003; 57: 384390.
  • 17
    Pollack A, Hanlon AL, Horwitz EM. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 11321136.
  • 18
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. NEJM. 1997; 337: 295300.
  • 19
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103106.
  • 20
    D'Amico AV, Moul JW, Carroll PR, et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004; 96: 509515.